BioSpace News Archive

Genetown

Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

June 18, 2024
·
4 min read
Business

The Foundation for the National Institutes of Health Names Recipients of the 2024 Charles A. Sanders, MD, Partnership Award

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

June 18, 2024
·
4 min read
Genetown

Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024

Cerevance will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.

June 18, 2024
·
2 min read
Deals

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics, Inc. today announced that on June 17, 2024, the Company granted an aggregate of 5,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4).

June 18, 2024
·
5 min read
Business

Prenetics Announces First Quarter 2024 Financial Results

Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2024.

June 18, 2024
·
15 min read
Drug Development

BaroPace Announces RelieveHFpEF-II, Its Phase I First-in-Human Trial of PressurePace™, Its Patent-Pending Pacemaker Control Algorithm for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with preserved ejection fraction (HFpEF).

June 18, 2024
·
3 min read
Business

Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024.

June 18, 2024
·
2 min read
Drug Development

Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

Theralase® Technologies Inc. is pleased to announce that in preclinical research, it’s lead drug formulation, Rutherrin®, has demonstrated an ability to increase the efficacy of immunotherapy.

June 18, 2024
·
9 min read
Drug Development

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. today announced positive topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

June 18, 2024
·
15 min read
BioCapital

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions

Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

June 18, 2024
·
2 min read